Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Marseille – page 27

1 490 clinical trials in Marseille, France across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Marseille at a glance
1 490
clinical trials
  • Research sites7
Type of trial
Recruitment status
Quick filters

1 490 trials in Marseille

Open in trial search

Plasma cell myeloma recurrent

Recruiting

Study Comparing Continuous and Fixed Duration Therapy with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Relapsed Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Soft tissue sarcoma

Recruiting

Study of cobimetinib and atezolizumab combination therapy in children and adults with advanced or metastatic soft tissue sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Centre Leon Berard

Systemic candida

Recruiting

Study on the Effectiveness and Safety of Fosmanogepix Compared to Caspofungin and Fluconazole for Adults with Candidemia or Invasive Candidiasis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Caspofungin
  • Sponsor:Basilea Pharmaceutica International AG Allschwil

Juvenile idiopathic arthritis

Recruiting

Study of Sarilumab for Children and Adolescents with Systemic Juvenile Idiopathic Arthritis (sJIA)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Sarilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Rectal cancer+1

Recruiting

Study on Encorafenib and Cetuximab for Patients with BRAF V600E-Mutated Localized Colon or Upper Rectum Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Fondation Franc.Cancerologie Digestive

Neoplasm+2

Recruiting

Study on APL-101 for Treating Advanced Solid Tumors and Non-Small Cell Lung Cancer with MET Changes in Patients

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:APL-101
  • Sponsor:Apollomics Inc.

Mantle cell lymphoma

Recruiting

Study on Glofitamab, Venetoclax, and Zanubrutinib for Patients with Untreated or Relapsed High-Risk Mantle Cell Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:LYSARC

Thermal burn

Recruiting

Study on the Effectiveness of EHSG-KF Skin Graft for Patients with Deep Partial and Full-Thickness Burns

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bilayer Engineered Collagen Hydrogel-Based Skin Graft Composed Of Autologous Keratinocytes And Fibroblasts
  • Sponsor:Cutiss AG

Non-small cell lung cancer

Recruiting

Study of Repotrectinib for Frail or Elderly Patients with Advanced Non-Small Cell Lung Cancer with ROS1 Gene Rearrangement

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Repotrectinib
  • Sponsor:Centre Hospitalier Intercommunal Toulon / La Seine-Sur-Mer

Premature rupture of membranes

Recruiting

Study on Nifedipine for Managing Preterm Premature Rupture of Membranes (PPROM) in Pregnant Women Before 34 Weeks

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Nifedipine
  • Sponsor:Assistance Publique Hopitaux De Paris

Myasthenia gravis

Recruiting

Study of Efgartigimod PH20 SC for Children Aged 2 to 17 with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Gastrointestinal stromal tumour

Recruiting

Study on the Effectiveness of Imatinib for Patients with Intermediate-Risk Gastrointestinal Stromal Tumor and High Genomic Grade Index

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Centre Hospitalier Regional De Marseille

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Marseille

What the registry says about research in the country

01 Oncology Research

Studies focusing on innovative treatments for head and neck squamous cell carcinoma, examining novel therapies and combinations with radiotherapy. Research includes investigations into endometrial cancer and bladder cancer treatments.

  • Advanced tumor treatments
  • Immunotherapy combinations
  • Targeted therapies

Particular emphasis on combining immunotherapy with conventional treatments for improved patient outcomes.

02 Cardiovascular and Metabolic Disorders

Innovative research addressing heart failure prevention and treatment of acute myocardial infarction. Studies include new approaches for managing hypertriglyceridemia and chronic kidney disease.

  • Preventive cardiology
  • Emergency cardiac care
  • Metabolic conditions

Focus on developing novel therapeutic approaches and improving patient outcomes in cardiovascular health.

03 Neurological Conditions

Clinical investigations into multiple sclerosis treatment strategies and management of essential tremor. Research includes innovative approaches for Dravet Syndrome and neurological disorders.

  • Movement disorders
  • Autoimmune conditions
  • Seizure management

Emphasis on developing targeted therapies for various neurological conditions affecting both adults and children.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.